menu
    • menu
    [{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Helsinn Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Fosnetupitant Chloride","moa":"Neurokinin 1 receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Berlin Chemie \/ Helsinn Group","highestDevelopmentStatusID":"12","companyTruncated":"Berlin Chemie \/ Helsinn Group"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Palonosetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Taiho Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Taiho Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Helsinn Advanced Synthesis","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Palonosetron","moa":"5-HT3A receptor","graph1":"Gastroenterology","graph2":"Approved","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fosun Pharmaceutical \/ Helsinn","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Pharmaceutical \/ Helsinn"},{"orgOrder":0,"company":"FarmaMondo","sponsor":"Helsinn Group","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Netupitant","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"FarmaMondo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"FarmaMondo \/ Helsinn Group","highestDevelopmentStatusID":"12","companyTruncated":"FarmaMondo \/ Helsinn Group"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Netupitant","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Advanced Synthesis \/ Not Applicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Netupitant","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Advanced Synthesis \/ Not Applicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Immedica Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Netupitant","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Immedica Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Advanced Synthesis \/ Immedica Pharma"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Netupitant","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Advanced Synthesis \/ Not Applicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Chugai Pharma Europe","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Fosnetupitant Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Advanced Synthesis \/ Chugai Pharma Europe"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Fosnetupitant Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Helsinn Advanced Synthesis \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Helsinn Advanced Synthesis \/ Not Applicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Palonosetron","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Avenacy \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Avenacy \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Palonosetron

    Menu

    Palonosetron

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avenacy

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Avenacy

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Avenacy Announces Launch of Palonosetron Hydrochloride Injection, USP in the U.S. Market

                            Details : Palonosetron HCl generic of Aloxi is a 5-HT3 receptor antagonist indicated as an antiemetic in adults for prevention of acute and delayed nausea and vomiting.

                            Brand Name : Aloxi-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 22, 2024

                            Lead Product(s) : Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosnetupitant Chloride,Palonosetron,Dexamethasone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Helsinn Group launches Akynzeo injection in US market

                            Details : Akynzeo (fosnetupitant/palonosetron) injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting.

                            Brand Name : Akynzeo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 26, 2024

                            Lead Product(s) : Fosnetupitant Chloride,Palonosetron,Dexamethasone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fosnetupitant Chloride,Palonosetron,Dexamethasone

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Chugai Pharma Europe

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Helsinn, Chugai renew partnership to sell AKYNZEO® in UK and Ireland

                            Details : The agreement aims to commercialise Akynzeo (combination of netupitant-palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in adult patients, in UK and Ireland.

                            Brand Name : Akynzeo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 12, 2024

                            Lead Product(s) : Fosnetupitant Chloride,Palonosetron,Dexamethasone

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Chugai Pharma Europe

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Helsinn Announces Publication of New Data Evaluating Impact Of NEPA (netupitant/palonosetron) On Hospital Cost...

                            Details : Akynzeo is a combination of netupitant, a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors and palonosetron, a 5-HT3 receptor antagonist with a strong binding affinity for this receptor. It is indicated for nausea due to cancer che...

                            Brand Name : Akynzeo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 03, 2023

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Immedica Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Helsinn and Immedica Enter Exclusive Partnership for Commercialisation of Cancer Supportive Care Products in C...

                            Details : Akynzeo (netupitant) is a 5-HT3 and NK1 receptor antagonist fixed combination approved in Europe in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin-based highly emetogenic chemotherapy and moderately emetogeni...

                            Brand Name : Akynzeo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 24, 2023

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Immedica Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Helsinn Publishes Results From A Secondary Analysis Of A Phase 3 Trial In Patients With CINV Helsinn Publishes...

                            Details : AKYNZEO (Netupitant) is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with cisplatin based highly emetogenic chemotherapy and moderately em...

                            Brand Name : Akynzeo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 04, 2023

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed

                            Helsinn Advanced Synthesis

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Helsinn Announces Presentation On CINV Trial at European Society for Medical Oncology (ESMO) Asia

                            Details : Akynzeo is the first and only 5-HT3 and NK1 receptor antagonist fixed combination approved in adults for the prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.

                            Brand Name : Akynzeo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 29, 2022

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            FarmaMondo

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed

                            FarmaMondo

                            Switzerland arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Helsinn Group

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Farma Mondo Group and Helsinn Sign Exclusive Partnership To Commercialize AKYNZEO® In The Baltic Region

                            Details : Under the terms of the agreement, Farma Mondo will manage the commercialization of AKYNZEO® in Estonia and Latvia. AKYNZEO® hard capsules (combination of netupitant/palonosetron), for the treatment of chemotherapy-induced nausea and vomiting (CINV) in ...

                            Brand Name : Akynzeo

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 28, 2022

                            Lead Product(s) : Netupitant,Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Helsinn Group

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Fosun Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed

                            Fosun Pharmaceutical

                            China arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Helsinn and Fosun Pharma Sign Exclusive License and Distribution Agreements For Aloxi®, Akynzeo® Oral, NEPA ...

                            Details : Helsinn will grant Fosun an exclusive license to distribute, promote and sell the following products in the aforesaid territory: Aloxi (Palonosetron hydrochloride), Akynzeo (Netupitant and Palonosetron hydrochloride) and NEPA (Fosnetupitant and Palonoset...

                            Brand Name : Aloxi

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 12, 2021

                            Lead Product(s) : Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Helsinn Advanced Synthesis

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed

                            Taiho Pharmaceutical

                            Japan arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palonosetron

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Taiho Pharma Submits Application for Additional Dosage and Administration of 5-HT3 Receptor Antagonist Aloxi®...

                            Details : Aloxi® has demonstrated its efficacy in delayed nausea and vomiting where available agents have hitherto provided insufficient effects.

                            Brand Name : Aloxi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 15, 2020

                            Lead Product(s) : Palonosetron

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth